Table 1 Clinico-pathological characteristics of the included cases in the ATRX-deficient and ATRX-intact groups.
ATRX-deficient | ATRX-intact | |
|---|---|---|
Total number of cases | 12 (100%) | 13 (100%) |
Age—mean (range), years | 61.08 (34–87) | 50.85 (36–63) |
Sex | ||
Male | 8 (66.7%) | 9 (69.2%) |
Female | 4 (33.3%) | 4 (30.8%) |
Localization | ||
Supratentorial | 10 (83.3%) | 12 (92.3%) |
Cerebellar | 1 (8.3%) | 1 (7.7%) |
Spinal | 1 (8.3%) | – |
Recurrent tumor | 2 (16.7%) | 5 (38.5%) |
Median overall survival (months) | 5.03 | 14.00 |
Diagnosis | ||
High-grade astrocytoma with piloid features | 1 (8.3%) | – |
Astrocytoma, NEC (G3) | 1 (8.3%) | – |
Glioblastoma, IDH-wildtype (G4) | 10 (83.3%) | 13 (100%) |
Giant cells | ||
Inconspicuous | 5 (41.7%) | 10 (76.9%) |
< 30% | 5 (41.7%) | 2 (15.4%) |
> 30% | 2 (16.7%) | 1 (7.7%) |
Therapy | ||
No | 3 (25%) | 0 (0%) |
Radiotherapy | 9 (75%) | 13 (100%) |
Chemotherapy | 7 (58.3%) | 13 (100%) |
Bevacizumab | 1 (9.1%) | 12 (92.3%) |
